Immunotherapy before surgery boosts survival for for liver cancer patients, clinical research finds

Immune checkpoint inhibitor (ICI) therapy before surgery for hepatocellular carcinoma (HCC) may produce major pathological response in about one-third of the surgical patients. The clinical and pre-clinical research highlighted that the formation…

Continue Reading

News Source: medicalxpress.com